Navigation Links
Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
Date:10/2/2008

GOTEBORG, Sweden, October 2 /PRNewswire/ -- Calabar AB announced today that their Phase II repeated dose study in xerostomia ("dry mouth") patients has been initiated. Specifically, the drug will be studied in 45 dry mouth patients between the ages of 20 to 75. The objective of the study is to select a dose for evaluation in a succeeding Phase III efficacy study.

Xalieve(TM) is a gel containing the cholinesterase inhibitor physostigmine. It is administered locally in the mouth where physostigmine diffuses through the mucosa reaching the minor glands. By inhibiting cholinesterase, acetylcholine accumulates and the elevated concentrations stimulate the muscarinic receptors in the minor glands, improving saliva production. Unlike systemically administered drugs, the local route of administration limits adverse events.

"Xalieve(TM) offers a completely new approach in treating dry mouth and we are very excited about this Phase II study," said Mr. Fredrik Rook, VP Business Development of Calabar. "Xerostomia is not getting the attention it deserves. These patients are experiencing dramatic decrease in quality of life, such as difficulty in swallowing and speaking, and a burning sensation in the mouth. Xalieve(TM) has the possibility to radically improve the life of millions of people suffering from dry mouth."

About Calabar AB:

Calabar is a privately-held company committed to developing pharmaceutical products addressing the significant unmet needs of xerostomia "dry mouth". The company's product Xalieve(TM) is a locally administered formulation of the cholinesterase inhibitor physostigmine, which has been shown to effectively increase salivary flow. The company is part of the Karolinska Development AB portfolio. For more information, please visit http://www.calabar.se

Contact:

VP Business Development,

Fredrik Rook,

+46-8-524-860-38,

fredrik.rook@calabar.se .


'/>"/>
SOURCE Calabar AB
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
2. Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
3. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
4. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Two New Alzheimers Disease Studies Show Advances Against Different Treatment Targets
6. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
7. Novel Approach May Protect Against Heart Attack Injury
8. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
9. Grocery Manufacturers Association: Study Signals Progress in Battle Against Obesity
10. Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 Abdominal Aortic Aneurysm Repair Devices Market was ... 2022, Globally, registering a CAGR of 5.1% from 2016 to 2022. The endovascular stent ... dominate the market during the study period. Continue Reading ... ... ...
(Date:3/24/2017)... 2017 New England Pediatric Device Consortium (NEPDC) ... including funding and in-kind service towards the commercialization of ... "Making blood draws less traumatic for children could ... experience better.  We,re looking forward to working with Velano ... care for the kids we treat," said Ann-Christine ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global Wound ... report to their offering. ... The global wound care market was worth $24,482.9 million in 2015 and ... Among the various wound care products type, the advanced wound ... 2015. Among the various applications, surgical wound segment held the largest share ...
Breaking Medicine Technology:
(Date:3/25/2017)... ... 2017 , ... Getting earned media coverage meaningful for Garden Media Group's clients ... the year, Garden Media aims to provide material helpful to clients’ goals and bottom ... client’s key messages to gain coveted media placements, Garden Media wows clients year-round. ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... from third world countries to hospitals in the United States, it’s a threat ... on the current obstacles facing infection prevention and offers strategies for the healthcare ...
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards for eating ... of disordered eating, announced today that the 2017 Symposium set a new attendance record ... countries converged on the Green Valley Resort in Las Vegas. , “We are ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
Breaking Medicine News(10 mins):